Citizens Financial Group Inc Lineage Cell Therapeutics, Inc. Transaction History
Citizens Financial Group Inc
- $7.13 Billion
- Q3 2025
A detailed history of Citizens Financial Group Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Citizens Financial Group Inc holds 15,000 shares of LCTX stock, worth $28,200. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,000Holding current value
$28,200% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
136Shares Held
99.2MCall Options Held
368KPut Options Held
0-
Broadwood Capital Inc New York, NY49.6MShares$93.2 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$18 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.48MShares$15.9 Million0.0% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$10.1 Million6.02% of portfolio
-
Comerica Bank4.6MShares$8.65 Million0.02% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $319M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...